

XPhyto Therapeutics Corp.

07:45 09 Dec 2019

XPhyto Therapeutics' oral thin film delivery system to focus on developing epilepsy products

XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) said Monday that the development of epilepsy treatment products using its proprietary oral thin film delivery system will be a "priority" initiative for 2020.

The science-focused cannabis company said in a statement that it is focusing on generic cannabidiol-based dissolvable oral wafers for the treatment of severe childhood forms of epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome.

Challenging to diagnose and treat, patients suffering these two forms of severe epilepsy often develop severe neurologic, intellectual, and behavioral disorders that progressively worsen.

READ: XPhyto Therapeutics focused on scientific approach to cannabis in Germany and Canada

Current FDA/EMA-approved CBD-based treatment for Dravet and Lennox-Gastaut is founded on a plant extract oil containing 100 mg of CBD per millilitre. Based on initial dissolution testing using XPhyto's proprietary thin film drug delivery system, previously announced on November 11, the company's oral delivery system may yield as much as a "10 to 20x increase in bioavailability of CBD" over existing oil delivery methods, said the company.

"XPhyto believes that an efficient and well-defined dosage form is the future of cannabis-based medicine. High bioavailability with controlled and reproducible delivery is critical," said XPhyto Therapeutics CEO Hugh Rogers in a statement.

"Our initial results suggest significant potential timing and efficiency advantages over conventional delivery methods," he added.

Price: 2.09

Market Cap: \$101.71 m

1 Year Share Price Graph



August 2019 November 2019 February 2020

Share Information

Code: XPHY

Listing: CSE

52 week	High	Low
	2.23	0.73

Sector: Cannabis

Website: www.xphyto.com

Company Synopsis:

XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto's 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM).

action@proactiveinvestors.com

XPhyto's thin film drug delivery system was developed by its wholly-owned German subsidiary, Vektor Pharma TF GmbH. Vektor is a narcotics manufacturer, importer, and researcher located near Munich, Germany.

Vektor's previous development work has included narcotics delivery systems for conventional oncology and non-

oncology pain treatment, such as Fentanyl, Hydromorphone, and Oxycodone, and more recently, the development of efficient cannabis delivery and dosage systems.

Oral thin film drug delivery is a large and hyper-growth international industry which provides an alternative to conventional solid and liquid oral dosage forms. The global market for thin film drug manufacturing will be worth \$15.984 billion by 2024, and is estimated to expand at a solid 9% compound annual growth rate between 2019 and 2024, according to Transparency Market Research

XPhyto Therapeutics is a science-focused cannabis company developing analytical testing, processing, and formulation capability in Canada. In addition to subsidiary Vektor Pharma TF GmbH, XPhyto has also acquired 100% ownership of the German cannabis company Bunker Pflanzenextrakte GmbH. The company operates from a decommissioned German Air Force command center and nuclear bunker near Munich, hence its name, which is the largest cannabis laboratory in Germany.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to

Twenty	Five	Thousand	dollars	(\$25,000).
--------	------	----------	---------	-------------